Overview
Miller-Dieker syndrome (MDS), also known as Miller-Dieker lissencephaly syndrome (MDLS), is a rare genetic disorder characterized by classical lissencephaly (smooth brain) and distinctive facial features. It results from a deletion of genetic material on the short arm of chromosome 17 (17p13.3), which includes the PAFAH1B1 (LIS1) gene and the YWHAE gene. The deletion of LIS1 is primarily responsible for the lissencephaly, while loss of additional genes in the deleted region contributes to the characteristic craniofacial abnormalities and other features. The brain malformation arises from defective neuronal migration during embryonic development, resulting in a smooth or nearly smooth cerebral surface with a thickened cortex and absent or reduced gyri and sulci. The syndrome primarily affects the central nervous system, leading to severe intellectual disability, profound developmental delay, and seizures that typically begin in infancy and are often refractory to treatment. Affected individuals usually have significant hypotonia (low muscle tone) that may progress to spasticity. Characteristic facial features include a prominent forehead, bitemporal hollowing, short nose with upturned nares, a thickened upper lip, and a small jaw (micrognathia). Microcephaly (abnormally small head) is also commonly present. Additional features may include feeding difficulties, failure to thrive, and congenital heart defects in some cases. The prognosis for Miller-Dieker syndrome is poor, with most affected children surviving only into early childhood, though some may live longer with supportive care. There is currently no cure or disease-modifying treatment. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications, nutritional support (often requiring gastrostomy tube feeding), physical therapy, and management of respiratory complications. Genetic counseling is important for families, as the deletion may arise de novo or may result from a balanced chromosomal rearrangement in a parent, which carries a significant recurrence risk.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Miller-Dieker syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Miller-Dieker syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Miller-Dieker syndrome.
Community
No community posts yet. Be the first to share your experience with Miller-Dieker syndrome.
Start the conversation →Latest news about Miller-Dieker syndrome
No recent news articles for Miller-Dieker syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Miller-Dieker syndrome
What is Miller-Dieker syndrome?
Miller-Dieker syndrome (MDS), also known as Miller-Dieker lissencephaly syndrome (MDLS), is a rare genetic disorder characterized by classical lissencephaly (smooth brain) and distinctive facial features. It results from a deletion of genetic material on the short arm of chromosome 17 (17p13.3), which includes the PAFAH1B1 (LIS1) gene and the YWHAE gene. The deletion of LIS1 is primarily responsible for the lissencephaly, while loss of additional genes in the deleted region contributes to the characteristic craniofacial abnormalities and other features. The brain malformation arises from defec
How is Miller-Dieker syndrome inherited?
Miller-Dieker syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Miller-Dieker syndrome typically begin?
Typical onset of Miller-Dieker syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Miller-Dieker syndrome?
1 specialists and care centers treating Miller-Dieker syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.